Newbridge Financial Services Group’s Alaunos Therapeutics TCRT Stock Holding History

Newbridge Financial Services Group’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47	Hold	21	–	–	﹤0.01%	1210
2026 Q1	$60	Hold	21	–	–	﹤0.01%	1158
2025 Q4	$68	Sell	21 -3	-13%	-$10	﹤0.01%	1156
2025 Q3	$58	Hold	24	–	–	﹤0.01%	1267
2025 Q2	$116	Hold	24	–	–	﹤0.01%	1279
2025 Q1	$35	Hold	24	–	–	﹤0.01%	1027
2024 Q4	$46	Hold	24	–	–	﹤0.01%	1119
2024 Q3	$77	Sell	24 -1	-4%	-$4	﹤0.01%	642
2024 Q2	$176	Hold	25	–	–	﹤0.01%	1048
2024 Q1	$456	Hold	25	–	–	﹤0.01%	1097
2023 Q4	$269	Hold	25	–	–	﹤0.01%	1070
2023 Q3	$501	Sell	25 -14	-36%	-$603	﹤0.01%	1204
2023 Q2	$2.96K	Hold	39	–	–	﹤0.01%	1093
2023 Q1	$3.65K	Hold	39	–	–	﹤0.01%	1121
2022 Q4	$3.77K	Hold	39	–	–	﹤0.01%	1113
2022 Q3	$10K	Hold	39	–	–	0.01%	892
2022 Q2	$7K	Hold	39	–	–	﹤0.01%	952
2022 Q1	$4K	Hold	39	–	–	﹤0.01%	1159
2021 Q4	$6K	Hold	39	–	–	﹤0.01%	1042
2021 Q3	$11K	Hold	39	–	–	0.01%	856
2021 Q2	$15K	Hold	39	–	–	0.01%	864
2021 Q1	$21K	Hold	39	–	–	0.02%	683
2020 Q4	$15K	Hold	39	–	–	0.01%	620
2020 Q3	$15K	Buy	+39	New	+$17.2K	0.01%	583

Other funds holding TCRT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Newbridge Financial Services Group's TCRT Position: Q2 2026 in Review

Newbridge Financial Services Group held its Alaunos Therapeutics (TCRT) position steady in Q2 2026 at 21 shares worth $47. The position accounts for ﹤0.01% of the portfolio, ranked #1210.

Newbridge Financial Services Group first reported a position in TCRT in Q3 2020 and has held it in 24 quarters since. The position peaked at $21K in Q1 2021. 29 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.

Newbridge Financial Services Group held 21 shares of Alaunos Therapeutics worth $47 as of Q2 2026.
Newbridge Financial Services Group left its Alaunos Therapeutics share count unchanged in Q2 2026.
Alaunos Therapeutics made up ﹤0.01% of Newbridge Financial Services Group's portfolio in Q2 2026, its #1210 holding.
Newbridge Financial Services Group first reported a position in Alaunos Therapeutics in Q3 2020 and has held it in 24 quarters since.
Newbridge Financial Services Group's Alaunos Therapeutics position peaked at $21K in Q1 2021.
29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.

Based on Newbridge Financial Services Group's 13F filing for Q2 2026, filed 14 Aug 2026.